A multicenter retrospective observational study assessing the efficacy and safety of high-dose IVI with ferric carboxymaltose in patients with chronic very severe sideropenic anemias
Latest Information Update: 11 Jul 2021
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions; Therapeutic Use
- 11 Jul 2021 New trial record